-DOCSTART-	O

Title	O
:	O
Severe	B-I
Acute	I-I
Respiratory	I-I
Syndrome	I-I
Coronavirus	I-I
2	I-I
Convalescent	I-I
Plasma	I-I
Versus	O
Standard	B-C
Plasma	I-C
in	O
Coronavirus	B-P
Disease	I-P
2019	I-P
Infected	I-P
Hospitalized	I-P
Patients	I-P
in	I-P
New	I-P
York	I-P
:	O
A	O
Double	O
-	O
Blind	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
Double	O
-	O
blind	O
randomized	O
controlled	O
trial	O
.	O

Hospital	O
in	O
New	O
York	O
.	O

Patients	B-P
with	I-P
polymerase	I-P
chain	I-P
reaction	I-P
documented	I-P
coronavirus	I-P
disease	I-P
2019	I-P
infection	I-P
.	O

Patients	O
were	O
randomized	O
(	O
4	O
:	O
1	O
)	O
to	O
receive	O
2	B-I
U	I-I
of	I-I
convalescent	I-I
plasma	I-I
versus	O
standard	B-C
plasma	I-C
.	O

Antibodies	B-O
to	I-O
severe	I-O
acute	I-O
respiratory	I-O
syndrome	I-O
coronavirus	I-O
2	I-O
were	O
measured	O
in	O
plasma	O
units	O
and	O
in	O
trial	O
recipients	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Ammonium	B-I
Chloride	I-I
in	O
addition	O
to	O
standard	B-I
of	I-I
care	I-I
in	O
outpatients	B-P
and	I-P
hospitalized	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
:	O
A	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
double	O
-	O
blind	O
,	O
single	O
-	O
center	O
study	O
,	O
we	O
enrolled	O
patients	B-P
with	I-P
positive	I-P
PCR	I-P
test	I-P
and	I-P
/	I-P
or	I-P
CT	I-P
findings	I-P
for	I-P
COVID	I-P
-	I-P
19	I-P
.	O

The	O
participants	O
of	O
each	O
group	O
were	O
randomly	O
assigned	O
to	O
Diphenhydramine	B-I
Compound	I-I
(	O
Diphenhydramine	B-I
+	O
Ammonium	B-I
Chloride	I-I
)	O
plus	O
standard	B-I
of	I-I
care	I-I
or	O
to	O
Diphenhydramine	B-C
alone	I-C
and	O
standard	B-C
of	I-C
care	I-C
groups	O
.	O

The	O
primary	O
outcome	O
was	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
within	O
30	O
days	O
of	O
randomization	O
.	O

Secondary	O
outcomes	O
include	O
viral	B-O
burden	I-O
,	O
clinical	B-O
status	I-O
,	O
assessed	O
by	O
a	B-O
5	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
,	O
and	O
length	B-O
of	I-O
stay	I-O
in	O
hospitalized	O
patients	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Early	B-I
Treatment	I-I
With	I-I
Hydroxychloroquine	I-I
or	O
Lopinavir	B-I
and	O
Ritonavir	B-I
on	O
Risk	O
of	O
Hospitalization	O
Among	O
Patients	B-P
With	I-P
COVID	I-P
-	I-P
19	I-P
:	O
The	O
TOGETHER	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
clinical	O
trial	O
was	O
conducted	O
in	O
Brazil	O
.	O

Recently	B-P
symptomatic	I-P
adults	I-P
diagnosed	I-P
with	I-P
respiratory	I-P
symptoms	I-P
from	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
were	O
enrolled	O
between	O
June	O
2	O
and	O
September	O
30	O
,	O
2020	O
.	O

The	O
planned	O
sample	O
size	O
was	O
1476	O
patients	O
,	O
with	O
interim	O
analyses	O
planned	O
after	O
500	O
patients	O
were	O
enrolled	O
.	O

The	O
trial	O
was	O
stopped	O
after	O
the	O
interim	O
analysis	O
for	O
futility	O
with	O
a	O
sample	O
size	O
of	O
685	O
patients	O
.	O

Statistical	O
analysis	O
was	O
performed	O
in	O
December	O
2020	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
hydroxychloroquine	B-I
(	O
800	O
mg	O
loading	O
dose	O
,	O
then	O
400	O
mg	O
daily	O
for	O
9	O
days	O
)	O
,	O
lopinavir	B-I
-	O
ritonavir	B-I
(	O
loading	O
dose	O
of	O
800	O
mg	O
and	O
200	O
mg	O
,	O
respectively	O
,	O
every	O
12	O
hours	O
followed	O
by	O
400	O
mg	O
and	O
100	O
mg	O
,	O
respectively	O
,	O
every	O
12	O
hours	O
for	O
the	O
next	O
9	O
days	O
)	O
,	O
or	O
placebo	B-C
.	O

The	O
primary	O
outcomes	O
were	O
COVID	B-O
-	I-O
19	I-O
-	I-O
associated	I-O
hospitalization	I-O
and	O
death	B-O
assessed	O
at	O
90	O
days	O
after	O
randomization	O
.	O

COVID	B-O
-	I-O
19	I-O
-	I-O
associated	I-O
hospitalization	I-O
was	O
analyzed	O
with	O
a	O
Cox	O
proportional	O
hazards	O
model	O
.	O

The	O
trial	O
included	O
the	O
following	O
secondary	O
outcomes	O
:	O
all	B-O
-	I-O
cause	I-O
hospitalization	I-O
,	O
viral	B-O
clearance	I-O
,	O
symptom	B-O
resolution	I-O
,	O
and	O
adverse	B-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Efficacy	O
of	O
Computerized	B-I
Cognitive	I-I
Behavioral	I-I
Therapy	I-I
for	O
Depressive	O
and	O
Anxiety	O
Symptoms	O
in	O
Patients	B-P
With	I-P
COVID	I-P
-	I-P
19	I-P
:	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
We	O
customized	O
a	B-I
cCBT	I-I
program	I-I
focused	O
on	O
improving	O
depressive	O
and	O
anxiety	O
symptoms	O
among	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
,	O
and	O
then	O
,	O
we	O
assessed	O
its	O
effectiveness	O
.	O

Screening	O
was	O
based	O
on	O
symptoms	O
of	O
depression	O
or	O
anxiety	O
for	O
patients	O
who	O
scored	O
?7	O
on	O
the	O
Hamilton	O
Depression	O
Rating	O
Scale	O
(	O
HAMD17	O
)	O
or	O
the	O
Hamilton	O
Anxiety	O
Scale	O
(	O
HAMA	O
)	O
.	O

A	B-P
total	I-P
of	I-P
252	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
at	I-P
five	I-P
sites	I-P
were	O
randomized	O
into	O
two	O
groups	O
:	O
cCBT	B-I
+	O
treatment	B-I
as	I-I
usual	I-I
(	I-I
TAU	I-I
;	O
n=126	O
)	O
and	O
TAU	B-C
without	O
cCBT	B-C
(	O
n=126	O
)	O
.	O

The	B-I
cCBT	I-I
+	O
TAU	B-I
group	O
received	O
the	B-I
cCBT	I-I
intervention	I-I
program	I-I
for	O
1	O
week	O
.	O

The	O
primary	O
efficacy	O
measures	O
were	O
the	B-O
HAMD17	I-O
and	O
HAMA	B-O
scores	I-O
.	O

The	O
secondary	O
outcome	O
measures	O
were	O
the	B-O
Self	I-O
-	I-O
Rating	I-O
Depression	I-O
Scale	I-O
(	I-O
SDS	I-O
)	I-O
,	O
Self	B-O
-	I-O
Rating	I-O
Anxiety	I-O
Scale	I-O
(	I-O
SAS	I-O
)	I-O
,	O
and	O
Athens	B-O
Insomnia	I-O
Scale	I-O
(	I-O
AIS	I-O
)	I-O
.	O

Assessments	O
were	O
carried	O
out	O
pre	O
-	O
and	O
postintervention	O
.	O

The	B-O
patients	I-O
'	I-O
symptoms	I-O
of	I-O
anxiety	I-O
and	O
depression	B-O
in	O
one	O
of	O
the	O
centers	O
were	O
assessed	O
again	O
within	O
1	O
month	O
after	O
the	O
postintervention	O
assessment	O
.	O

-DOCSTART-	O

Title	O
:	O
Favipiravir	B-I
in	O
the	O
treatment	O
of	O
patients	B-P
with	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
RNA	I-P
recurrent	I-P
positive	I-P
after	I-P
discharge	I-P
:	O
A	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
randomized	O
trial	O
.	O

METHODS	O
:	O
This	O
is	O
a	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
randomized	O
controlled	O
trial	O
in	O
SARS	B-P
-	I-P
CoV	I-P
-	I-P
2	I-P
RNA	I-P
re	I-P
-	I-P
positive	I-P
patients	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
2	O
:	O
1	O
ratio	O
to	O
receive	O
either	O
favipiravir	B-I
,	O
in	O
addition	O
to	O
standard	B-I
care	I-I
,	O
or	O
standard	B-C
care	I-C
alone	I-C
.	O

The	O
primary	O
outcome	O
was	O
time	B-O
to	I-O
achieve	I-O
a	I-O
consecutive	I-O
twice	I-O
(	I-O
at	I-O
intervals	I-O
of	I-O
more	I-O
than	I-O
24	I-O
h	I-O
)	I-O
negative	I-O
RT	I-O
-	I-O
PCR	I-O
result	I-O
for	I-O
SARS	I-O
-	I-O
CoV	I-O
-	I-O
2	I-O
RNA	I-O
in	I-O
nasopharyngeal	I-O
swab	I-O
and	O
sputum	B-O
sample	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
the	O
effectiveness	O
and	O
safety	O
of	O
adding	O
ivermectin	B-I
to	O
treatment	O
in	O
severe	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
severe	I-P
COVID19	I-P
pneumonia	I-P
were	O
included	O
in	O
the	O
study	O
,	O
which	O
was	O
planned	O
as	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
,	O
single	O
-	O
blind	O
phase	O
3	O
study	O
.	O

Two	O
groups	O
,	O
the	O
study	O
group	O
and	O
the	O
control	O
group	O
,	O
took	O
part	O
in	O
the	O
study	O
.	O

Ivermectin	B-I
200	O
mcg	O
/	O
kg	O
/	O
day	O
for	O
5	O
days	O
in	O
the	O
form	O
of	O
a	O
solution	O
prepared	O
for	O
enteral	O
use	O
added	O
to	O
the	B-I
reference	I-I
treatment	I-I
protocol	I-I
-	O
hydroxychloroquine	B-I
+	O
favipiravir	B-I
+	O
azithromycin	B-I
-	O
of	O
patients	O
included	O
in	O
the	O
study	O
group	O
.	O

Patients	O
in	O
the	O
control	O
group	O
were	O
given	O
only	B-C
reference	I-C
treatment	I-C
with	I-C
3	I-C
other	I-C
drugs	I-C
without	I-C
ivermectin	I-C
.	O

The	O
presence	O
of	O
mutations	O
was	O
investigated	O
by	O
performing	O
sequence	O
analysis	O
in	O
the	O
mdr1	O
/	O
abcab1	O
gene	O
with	O
the	O
Sanger	O
method	O
in	O
patients	O
included	O
in	O
the	O
study	O
group	O
according	O
to	O
randomization	O
.	O

Patients	O
with	O
mutations	O
were	O
excluded	O
from	O
the	O
study	O
and	O
ivermectin	B-I
treatment	I-I
was	O
not	O
continued	O
.	O

Patients	O
were	O
followed	O
for	O
5	O
days	O
after	O
treatment	O
.	O

At	O
the	O
end	O
of	O
the	O
treatment	O
and	O
follow	O
-	O
up	O
period	O
,	O
clinical	B-O
response	I-O
and	O
changes	O
in	O
laboratory	B-O
parameters	I-O
were	O
evaluated	O
.	O

-DOCSTART-	O

Title	O
:	O
Standard	B-C
Care	I-C
Versus	O
Awake	B-I
Prone	I-I
Position	I-I
in	O
Adult	B-P
Nonintubated	I-P
Patients	I-P
With	I-P
Acute	I-P
Hypoxemic	I-P
Respiratory	I-P
Failure	I-P
Secondary	I-P
to	I-P
COVID	I-P
-	I-P
19	I-P
Infection	I-P
-	O
A	O
Multicenter	O
Feasibility	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
60	B-P
patients	I-P
with	I-P
acute	I-P
hypoxic	I-P
respiratory	I-P
failure	I-P
secondary	I-P
to	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
requiring	I-P
4	I-P
or	I-P
more	I-P
liters	I-P
of	I-P
oxygen	I-P
to	I-P
maintain	I-P
a	I-P
saturation	I-P
of	I-P
?92	I-P
%	I-P
were	O
recruited	O
in	O
this	O
study	O
.	O

Thirty	O
patients	O
each	O
were	O
randomized	O
to	O
either	O
standard	B-C
care	I-C
or	O
awake	B-I
prone	I-I
group	O
.	O

Patients	O
randomized	O
to	O
the	B-I
prone	I-I
group	O
were	O
encouraged	O
to	O
self	O
-	O
prone	O
for	O
at	O
least	O
6	O
hours	O
a	O
day	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
adhering	I-O
to	I-O
the	I-O
protocol	I-O
in	O
each	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Ivermectin	B-I
in	O
combination	O
with	O
doxycycline	B-I
for	O
treating	O
COVID	O
-	O
19	O
symptoms	O
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
blinded	O
,	O
placebo	O
-	O
controlled	O
trial	O
in	O
patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
symptoms	I-P
randomly	O
assigned	O
to	O
treatment	O
(	O
n	O
=	O
200	O
)	O
and	O
placebo	B-C
(	O
n	O
=	O
200	O
)	O
groups	O
.	O

The	O
primary	O
outcome	O
was	O
duration	B-O
from	I-O
treatment	I-O
to	I-O
clinical	I-O
recovery	I-O
.	O

Secondary	O
outcomes	O
were	O
disease	B-O
progression	I-O
and	O
persistent	B-O
COVID	I-O
-	I-O
19	I-O
positivity	I-O
by	I-O
RT	I-O
-	I-O
PCR	I-O
.	O

METHODS	O
:	O
Dryad	O
.	O

doi	O
:	O
10	O
.	O
5061	O
/	O
dryad	O
.	O
qjq2bvqf6	O
.	O

-DOCSTART-	O

Title	O
:	O
Cytokine	B-I
adsorption	I-I
in	O
patients	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
requiring	I-P
extracorporeal	I-P
membrane	I-P
oxygenation	I-P
(	O
CYCOV	O
)	O
:	O
a	O
single	O
centre	O
,	O
open	O
-	O
label	O
,	O
randomised	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
single	O
-	O
centre	O
,	O
open	O
-	O
label	O
,	O
randomised	O
,	O
controlled	O
trial	O
to	O
investigate	O
cytokine	B-I
adsorption	I-I
in	O
adult	B-P
patients	I-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
requiring	I-P
ECMO	I-P
.	O

Patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
selected	I-P
for	I-P
ECMO	I-P
at	I-P
the	I-P
Freiburg	I-P
University	I-P
Medical	I-P
Center	I-P
(	I-P
Freiburg	I-P
,	I-P
Germany	I-P
)	I-P
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
to	O
receive	O
cytokine	B-I
adsorption	I-I
using	O
the	B-I
CytoSorb	I-I
device	I-I
or	O
not	B-C
.	O

Randomisation	O
was	O
computer	O
-	O
generated	O
,	O
allocation	O
was	O
concealed	O
by	O
opaque	O
,	O
sequentially	O
numbered	O
sealed	O
envelopes	O
.	O

The	O
CytoSorb	O
device	O
was	O
incorporated	O
into	O
the	O
ECMO	O
circuit	O
before	O
connection	O
to	O
the	O
patient	O
circuit	O
,	O
replaced	O
every	O
24	O
h	O
,	O
and	O
removed	O
after	O
72	O
h	O
.	O

The	O
primary	O
endpoint	O
was	O
serum	B-O
interleukin	I-O
-	I-O
6	I-O
(	I-O
IL	I-O
-	I-O
6	I-O
)	I-O
concentration	I-O
72	O
h	O
after	O
initiation	O
of	O
ECMO	O
analysed	O
by	O
intention	O
to	O
treat	O
.	O

Secondary	O
endpoints	O
included	O
30	B-O
-	I-O
day	I-O
survival	I-O
.	O

The	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
(	O
NCT04324528	O
)	O
and	O
the	O
German	O
Clinical	O
Trials	O
Register	O
(	O
DRKS00021300	O
)	O
and	O
is	O
closed	O
.	O

-DOCSTART-	O

Title	O
:	O
Dexamethasone	B-I
vs	O
methylprednisolone	B-I
high	O
dose	O
for	O
Covid	O
-	O
19	O
pneumonia	O
.	O

METHODS	O
:	O
Ambispective	O
cohort	O
study	O
with	O
survival	O
analysis	O
of	O
216	B-P
patients	I-P
diagnosed	I-P
with	I-P
severe	I-P
Covid	I-P
-	I-P
19	I-P
pneumonia	I-P
confirmed	I-P
by	I-P
polymerase	I-P
chain	I-P
reaction	I-P
for	I-P
SARS	I-P
-	I-P
CoV2	I-P
by	I-P
Berlin	I-P
protocol	I-P
,	I-P
who	I-P
were	I-P
hospitalized	I-P
in	I-P
a	I-P
high	I-P
-	I-P
complexity	I-P
clinic	I-P
in	I-P
Medelln	I-P
,	I-P
Colombia	I-P
.	O

The	O
patients	O
should	O
also	O
have	O
supplementary	O
oxygen	O
and	O
radiological	O
confirmation	O
of	O
Pneumonia	O
by	O
chest	O
tomography	O
.	O

Sample	O
size	O
was	O
not	O
calculated	O
since	O
the	O
total	O
population	O
that	O
met	O
the	O
inclusion	O
criteria	O
was	O
evaluated	O
.	O

111	O
patients	O
were	O
treated	O
with	O
the	O
institutional	O
protocol	O
with	O
intravenous	B-I
dexamethasone	I-I
6	O
mg	O
QD	O
for	O
seven	O
to	O
10	O
days	O
if	O
they	O
required	O
oxygen	O
.	O

Since	O
September	O
15	O
,	O
2020	O
,	O
the	O
hospitalization	O
protocol	O
of	O
the	O
clinic	O
was	O
modified	O
by	O
the	O
Infectious	O
Diseases	O
and	O
Pulmonology	O
service	O
,	O
recommending	O
a	B-I
high	I-I
dose	I-I
of	I-I
methylprednisolone	I-I
of	O
250	O
to	O
500	O
mg	O
every	O
day	O
for	O
three	O
days	O
with	O
a	O
subsequent	O
change	O
to	O
oral	O
prednisone	O
50	O
mg	O
every	O
day	O
for	O
14	O
days	O
.	O

The	O
protocol	O
was	O
not	O
applied	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
where	O
dexamethasone	B-I
continued	O
to	O
be	O
administered	O
.	O

The	B-O
clinical	I-O
outcome	I-O
and	O
differences	O
in	O
laboratory	B-O
results	I-O
of	O
the	O
patients	O
who	O
received	O
dexamethasone	B-I
vs	O
.	O
the	O
prospective	O
cohort	O
that	O
received	O
methylprednisolone	B-I
from	O
September	O
15	O
to	O
October	O
31	O
,	O
2020	O
,	O
were	O
evaluated	O
.	O

Follow	O
-	O
up	O
was	O
carried	O
out	O
by	O
outpatient	O
consultation	O
one	O
month	O
after	O
discharge	O
or	O
by	O
telephone	O
,	O
inquiring	O
about	O
readmission	B-O
or	O
living	B-O
-	I-O
dead	I-O
status	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Post	O
-	O
COVID	O
-	O
19	O
asthenic	O
syndrome	O
]	O
.	O

METHODS	O
:	O
The	O
study	O
included	O
129	B-P
patients	I-P
with	I-P
an	I-P
average	I-P
age	I-P
of	I-P
49	I-P
.	I-P
88	I-P
.	I-P

9	I-P
years	I-P
who	I-P
had	I-P
undergone	I-P
COVID	I-P
-	I-P
19	I-P
using	I-P
a	I-P
continuous	I-P
sample	I-P
method	I-P
.	O

Patients	O
for	O
the	O
study	O
were	O
selected	O
at	O
the	O
clinical	O
bases	O
of	O
outpatient	O
clinics	O
in	O
Samara	O
(	O
Russia	O
)	O
in	O
July	O
-	O
August	O
2020	O
.	O

All	O
patients	O
signed	O
an	O
informed	O
consent	O
form	O
prior	O
to	O
enrollment	O
.	O

Patients	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
in	O
the	O
main	O
group	O
(	O
n=64	O
)	O
,	O
ethylmethylhydroxypyridine	B-I
succinate	I-I
(	O
Neurox	B-I
)	O
was	O
prescribed	O
1	O
tablet	O
(	O
125	O
mg	O
)	O
3	O
times	O
a	O
day	O
for	O
4	O
weeks	O
;	O
in	O
the	O
comparison	O
group	O
(	O
n=65	O
)	O
,	O
medical	B-C
drugs	I-C
(	I-C
MD	I-C
)	I-C
did	O
not	O
contain	O
substances	O
from	O
the	O
pharmacological	O
group	O
related	O
to	O
antihypoxants	O
/	O
antioxidants	O
/	O
nootropics	O
.	O

Three	O
visits	O
(	O
V	O
)	O
were	O
conducted	O
:	O
the	O
first	O
(	O
V1	O
)	O
-	O
the	O
period	O
of	O
inclusion	O
,	O
the	O
second	O
(	O
V2	O
)	O
-	O
after	O
14	O
days	O
,	O
the	O
third	O
(	O
V3	O
)	O
-	O
on	O
the	O
28	O
th	O
day	O
from	O
the	O
start	O
of	O
therapy	O
.	O

The	B-O
dynamics	I-O
of	I-O
the	I-O
general	I-O
state	I-O
(	O
weakness	B-O
,	O
fatigue	B-O
,	O
concentration	B-O
,	O
dizziness	B-O
,	O
headache	B-O
,	O
sleep	B-O
disorders	I-O
)	O
were	O
evaluated	O
on	O
a	B-O
visual	I-O
-	I-O
analog	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
,	O
the	B-O
assessment	I-O
of	I-O
the	I-O
subjective	I-O
feeling	I-O
of	I-O
severity	I-O
of	I-O
asthenia	I-O
(	O
fatigue	B-O
,	O
physical	B-O
and	O
mental	B-O
fatigue	I-O
,	O
decreased	B-O
motivation	I-O
and	O
activity	B-O
)	O
-	O
on	O
Multidimensional	B-O
Fatigue	I-O
Inventory	I-O
(	I-O
MFI	I-O
-	I-O
20	I-O
)	I-O
,	O
cognitive	B-O
functions	I-O
-	O
on	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
vegetative	B-O
tone	I-O
-	O
according	O
to	O
the	B-O
Kerdo	I-O
index	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
sofosbuvir	B-I
/	O
velpatasvir	B-I
versus	O
the	B-C
standard	I-C
of	I-C
care	I-C
in	O
adults	B-P
hospitalized	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
single	O
-	O
centre	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
single	O
-	O
centre	O
,	O
randomized	O
,	O
open	O
-	O
labelled	O
,	O
prospective	O
clinical	O
trial	O
was	O
done	O
in	O
patients	B-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
admitted	I-P
to	I-P
Farabi	I-P
Hospital	I-P
in	I-P
Kermanshah	I-P
Province	I-P
,	I-P
Iran	I-P
.	O

Eligible	O
patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
the	B-I
SOF	I-I
/	O
VEL	B-I
arm	O
(	O
SOF	B-I
/	O
VEL	B-I
plus	O
the	B-I
national	I-I
standard	I-I
of	I-I
care	I-I
)	O
or	O
the	O
control	O
arm	O
(	O
the	B-C
national	I-C
standard	I-C
of	I-C
care	I-C
alone	I-C
)	O
.	O

The	O
main	O
outcome	O
of	O
the	O
study	O
was	O
the	B-O
mortality	I-O
on	O
Day	O
28	O
after	O
randomization	O
.	O

Secondary	O
outcomes	O
were	O
time	B-O
from	I-O
the	I-O
start	I-O
of	I-O
medication	I-O
to	I-O
clinical	I-O
improvement	I-O
,	O
hospital	B-O
length	I-O
of	I-O
stay	I-O
,	O
need	B-O
for	I-O
mechanical	I-O
ventilation	I-O
,	O
duration	B-O
of	I-O
mechanical	I-O
ventilation	I-O
and	O
conversion	B-O
of	I-O
RT	I-O
-	I-O
PCR	I-O
results	I-O
from	I-O
positive	I-O
to	I-O
negative	I-O
from	O
the	O
time	O
of	O
randomization	O
to	O
discharge	O
.	O

Adverse	B-O
events	I-O
were	O
evaluated	O
in	O
all	O
patients	O
who	O
started	O
their	O
assigned	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Colchicine	B-I
for	O
community	B-P
-	I-P
treated	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	O
COLCORONA	O
)	O
:	O
a	O
phase	O
3	O
,	O
randomised	O
,	O
double	O
-	O
blinded	O
,	O
adaptive	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
trial	O
.	O

METHODS	O
:	O
The	O
present	O
study	O
is	O
a	O
phase	O
3	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
adaptive	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
trial	O
.	O

The	O
study	O
was	O
done	O
in	O
Brazil	O
,	O
Canada	O
,	O
Greece	O
,	O
South	O
Africa	O
,	O
Spain	O
,	O
and	O
the	O
USA	O
,	O
and	O
was	O
led	O
by	O
the	O
Montreal	O
Heart	O
Institute	O
.	O

Patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
diagnosed	I-P
by	I-P
PCR	I-P
testing	I-P
or	I-P
clinical	I-P
criteria	I-P
who	I-P
were	I-P
not	I-P
being	I-P
treated	I-P
in	I-P
hospital	I-P
were	O
eligible	O
if	O
they	O
were	O
at	O
least	O
40	O
years	O
old	O
and	O
had	O
at	O
least	O
one	O
high	O
-	O
risk	O
characteristic	O
.	O

The	O
randomisation	O
list	O
was	O
computer	O
-	O
generated	O
by	O
an	O
unmasked	O
biostatistician	O
,	O
and	O
masked	O
randomisation	O
was	O
centralised	O
and	O
done	O
electronically	O
through	O
an	O
automated	O
interactive	O
web	O
-	O
response	O
system	O
.	O

The	O
allocation	O
sequence	O
was	O
unstratified	O
and	O
used	O
a	O
1	O
:	O
1	O
ratio	O
with	O
a	O
blocking	O
schema	O
and	O
block	O
sizes	O
of	O
six	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
orally	B-I
administered	I-I
colchicine	I-I
(	O
05	O
mg	O
twice	O
per	O
day	O
for	O
3	O
days	O
and	O
then	O
once	O
per	O
day	O
for	O
27	O
days	O
thereafter	O
)	O
or	O
matching	B-C
placebo	I-C
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	B-O
composite	I-O
of	I-O
death	I-O
or	O
hospital	B-O
admission	I-O
for	I-O
COVID	I-O
-	I-O
19	I-O
.	O

Vital	B-O
status	I-O
at	O
the	O
end	O
of	O
the	O
study	O
was	O
available	O
for	O
979	O
%	O
of	O
patients	O
.	O

The	O
analyses	O
were	O
done	O
according	O
to	O
the	O
intention	O
-	O
to	O
-	O
treat	O
principle	O
.	O

The	O
COLCORONA	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
(	O
NCT04322682	O
)	O
and	O
is	O
now	O
closed	O
to	O
new	O
participants	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
Single	I-I
Dose	I-I
of	I-I
Ivermectin	I-I
on	O
Viral	O
and	O
Clinical	O
Outcomes	O
in	O
Asymptomatic	B-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
Infected	I-P
Subjects	I-P
:	O
A	O
Pilot	O
Clinical	O
Trial	O
in	O
Lebanon	O
.	O

METHODS	O
:	O
A	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
in	O
100	B-P
asymptomatic	I-P
Lebanese	I-P
subjects	I-P
that	I-P
have	I-P
tested	I-P
positive	I-P
for	I-P
SARS	I-P
-	I-P
CoV2	I-P
.	O

Fifty	O
patients	O
received	O
standard	B-C
preventive	I-C
treatment	I-C
,	O
mainly	B-C
supplements	I-C
,	O
and	O
the	O
experimental	O
group	O
received	O
a	B-I
single	I-I
dose	I-I
(	I-I
according	I-I
to	I-I
body	I-I
weight	I-I
)	I-I
of	I-I
ivermectin	I-I
,	O
in	O
addition	O
to	O
the	B-I
same	I-I
supplements	I-I
the	O
control	O
group	O
received	O
.	O

-DOCSTART-	O

Title	O
:	O
Therapeutic	B-I
versus	O
prophylactic	B-C
anticoagulation	I-C
for	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
elevated	I-P
D	I-P
-	I-P
dimer	I-P
concentration	I-P
(	O
ACTION	O
)	O
:	O
an	O
open	O
-	O
label	O
,	O
multicentre	O
,	O
randomised	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
pragmatic	O
,	O
open	O
-	O
label	O
(	O
with	O
blinded	O
adjudication	O
)	O
,	O
multicentre	O
,	O
randomised	O
,	O
controlled	O
trial	O
,	O
at	O
31	O
sites	O
in	O
Brazil	O
.	O

Patients	B-P
(	I-P
aged	I-P
?18	I-P
years	I-P
)	I-P
hospitalised	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
elevated	I-P
D	I-P
-	I-P
dimer	I-P
concentration	I-P
,	I-P
and	I-P
who	I-P
had	I-P
COVID	I-P
-	I-P
19	I-P
symptoms	I-P
for	I-P
up	I-P
to	I-P
14	I-P
days	I-P
before	I-P
randomisation	I-P
,	O
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
to	O
receive	O
either	O
therapeutic	B-I
or	O
prophylactic	B-C
anticoagulation	I-C
.	O

Therapeutic	B-I
anticoagulation	I-I
was	O
in	B-I
-	I-I
hospital	I-I
oral	I-I
rivaroxaban	I-I
(	O
20	O
mg	O
or	O
15	O
mg	O
daily	O
)	O
for	O
stable	O
patients	O
,	O
or	O
initial	B-I
subcutaneous	I-I
enoxaparin	I-I
(	O
1	O
mg	O
/	O
kg	O
twice	O
per	O
day	O
)	O
or	O
intravenous	B-I
unfractionated	I-I
heparin	I-I
(	O
to	O
achieve	O
a	O
03	O
-	O
07	O
IU	O
/	O
mL	O
anti	O
-	O
Xa	O
concentration	O
)	O
for	O
clinically	O
unstable	O
patients	O
,	O
followed	O
by	O
rivaroxaban	B-I
to	O
day	O
30	O
.	O

Prophylactic	B-C
anticoagulation	I-C
was	O
standard	B-C
in	I-C
-	I-C
hospital	I-C
enoxaparin	I-C
or	O
unfractionated	B-C
heparin	I-C
.	O

The	O
primary	O
efficacy	O
outcome	O
was	O
a	O
hierarchical	O
analysis	O
of	O
time	B-O
to	I-O
death	I-O
,	O
duration	B-O
of	I-O
hospitalisation	I-O
,	O
or	O
duration	B-O
of	I-O
supplemental	I-O
oxygen	I-O
to	O
day	O
30	O
,	O
analysed	O
with	O
the	O
win	O
ratio	O
method	O
(	O
a	O
ratio	O
>	O
1	O
reflects	O
a	O
better	O
outcome	O
in	O
the	O
therapeutic	O
anticoagulation	O
group	O
)	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
primary	O
safety	O
outcome	O
was	O
major	B-O
or	O
clinically	B-O
relevant	I-O
non	I-O
-	I-O
major	I-O
bleeding	I-O
through	O
30	O
days	O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
(	O
NCT04394377	O
)	O
and	O
is	O
completed	O
.	O

